股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 ...

Core Viewpoint - Kubo Medical (02216) has seen a significant increase in stock price, rising over 9% during trading and currently up 5.86% at HKD 3.25, with a trading volume of HKD 11.79 million [1] Group 1: Company Actions - Kubo Medical announced plans to issue a total of 105 million subscription shares at a price of HKD 3.11 per share, representing a premium of approximately 1.3% over the previous trading day's closing price [1] - The net proceeds from this issuance are expected to be around HKD 327 million, which will be used for potential acquisitions in the medical device industry to continue expanding the product portfolio [1] - The company is actively seeking potential acquisition targets within the medical device sector and is currently in discussions with various parties [1] Group 2: Strategic Partnerships - Notably, Ying Tai Medical (01501) plans to invest approximately HKD 283 million to subscribe for about 91.09 million shares of Kubo Medical [1] - The announcement highlights that Kubo Medical has a rich product line in the non-vascular interventional field, and the subscription will further enhance the company's strategic positioning in this area [1]

Core Viewpoint - Kintor Pharmaceutical-B (02216) has seen a significant increase in stock price, rising over 9% during trading, with a current price of 3.25 HKD and a trading volume of 11.79 million HKD. The company announced plans to issue a total of 105 million subscription shares at a price of 3.11 HKD per share, representing a premium of approximately 1.3% over the previous closing price. The net proceeds of approximately 327 million HKD will be used for potential acquisitions in the medical device industry, as the company seeks to expand its product portfolio [1][1][1]. Group 1 - Kintor Pharmaceutical plans to issue 105 million subscription shares at 3.11 HKD each, raising approximately 327 million HKD for acquisitions [1][1][1]. - The stock price of Kintor Pharmaceutical has increased by over 9% during trading, reflecting positive market sentiment [1][1][1]. - The company is currently in discussions with various parties to identify potential acquisition targets in the medical device sector [1][1][1]. Group 2 - Ying Tai Medical (01501) intends to invest approximately 283 million HKD to subscribe for about 91.09 million shares of Kintor Pharmaceutical [1][1][1]. - The subscription is expected to enhance Kintor Pharmaceutical's strategic positioning in the non-vascular interventional field, where it already has a rich product line [1][1][1].

Core Viewpoint - The company, KPB Medical-B (02216.HK), has entered into a subscription agreement to issue 105.1 million shares at a price of HKD 3.11 per share, representing a premium of approximately 1.3% over the closing price of HKD 3.07 [1][2] Group 1: Subscription Details - The total number of shares to be issued represents about 19.90% of the company's existing share capital as of the announcement date and approximately 16.60% of the enlarged share capital post-issuance [1] - The subscription is backed by two parties: Shanghai Yingtai Medical Devices Co., Ltd., which is engaged in the manufacturing of cardiovascular interventional medical devices, and Hangzhou Linheng Qingrui Enterprise Management Partnership, focusing on enterprise management and development services [1] Group 2: Financial Implications - The total gross proceeds from the subscription are estimated to be approximately HKD 326.9 million, with net proceeds expected to be around HKD 326.5 million after expenses, translating to a net issue price of about HKD 3.106 per share [2] - The net proceeds are intended to fund potential acquisitions in the medical device industry to expand the product portfolio, thereby strengthening the company's liquidity and financial position [2] - The board believes that the subscription will enhance the equity base of the company, optimize its capital structure, and support sustainable development, aligning with the overall interests of the company and its shareholders [2]

Core Viewpoint - The company, Kubo Medical-B (02216), has entered into a subscription agreement to issue and allot a total of 105 million subscription shares at a price of HKD 3.11 per share, which represents a premium over the market price on the date of the announcement [1] Group 1: Subscription Details - The total number of subscription shares to be issued represents approximately 16.60% of the enlarged issued share capital of the company, assuming no changes in the issued share capital from the date of the announcement until completion, except for the shares arising from the subscription [1] - The subscription price of HKD 3.11 per share is approximately 1.3% higher than the closing price of HKD 3.07 per share on the Hong Kong Stock Exchange on the date of the announcement [1] Group 2: Financial Implications - The estimated net proceeds from the subscription, after deducting expenses, are approximately HKD 327 million, equating to a net issue price of about HKD 3.106 per subscription share [1] - The net proceeds are intended to fund potential acquisitions in the medical device industry to continuously expand the company's product portfolio [1]

Core Viewpoint - The company, Kubo Medical-B (02216), has announced a subscription agreement to issue 105 million shares at a price of HKD 3.11 per share, which represents a premium over the market price on the announcement date [1] Summary by Relevant Categories Subscription Agreement - The company has conditionally agreed to issue a total of 105 million subscription shares [1] - The subscription price of HKD 3.11 per share is approximately 1.3% higher than the closing price of HKD 3.07 on the Hong Kong Stock Exchange on the announcement date [1] - The total number of shares to be issued represents about 16.60% of the enlarged issued share capital of the company, assuming no changes in the issued share capital until completion [1] Financial Implications - The estimated net proceeds from the subscription, after expenses, are approximately HKD 327 million, equating to a net issue price of about HKD 3.106 per share [1] - The net proceeds are intended to fund potential acquisitions in the medical device industry to continuously expand the product portfolio [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 Broncus Holding Corporation （股份代號：2216) 堃 博醫療控股有限公司 （於開曼群島註冊成立的有限公司） 建議根據一般授權發行股份 於2025年10月10日，本公司與各認購方訂立認購協議，據此，本公司已有條件 同意配發及發行，及認購方已有條件同意認購合共105,108,015股認購股份，認 購價為每股認購股份3.11港元。 根據認購事項將予配發及發行的105,108,015股認購股份總數，佔(i)於本公告日 期本公司已發行股本之約19.90%；及(ii)透過發行認購股份擴大的本公司已發行 股本約16.60%（假設自本公告日期起直至完成本公司已發行股本並無變動，惟 因認購事項產生者除外）。認購股份將根據一般授權發行。 認購事項的所得款項總額總計將約為326.9百萬港元，而認購事項的所得款項淨 額總計（扣除 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定 ...

(Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立的有限公司 (Stock Code: 2216 / 股份代號: 2216) Broncus Holding Corporation 堃博医疗控股有限公司 25 September 2025 Dear Non-registered shareholder(s), Broncus Holding Corporation (the "Company") – Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter dated 20 May 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", the Company is writing to infor ...

Broncus Holding Corporation 堃博医疗控股有限公司 (Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立的有限公司 ) (Stock Code: 2216 / 股份代號: 2216) 25 September 2025 Dear registered shareholder(s), Broncus Holding Corporation (the "Company") – Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications (Note 1) With reference to the notification letter dated 20 May 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications ", the Company is writing ...